A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder FDA Decision: Denali Therapeutics (DNLI)

The Phase 2 date for A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder by Denali Therapeutics (DNLI) is scheduled for March 30, 2028. This is the target date for the FDA to make a decision on this application.

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder is being developed by Denali Therapeutics for the treatment of its target indication. It is currently in Phase 2 clinical trials.

If A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder receives FDA approval, Denali Therapeutics (DNLI) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 2 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for DNLI on DilutionWatch at dilutionwatch.com/stock/DNLI.html.

You can view the full BiotechSign company profile for Denali Therapeutics (DNLI) at biotechsign.com/app/company/DNLI, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.